Daily Archives: November 4, 2021 | LinksMedicus Free Medical News & Perspectives

Observational study showed J&J single shot vaccine had an effectiveness of 74% against symptomatic Covid-19.

4 Nov, 2021 | 10:08h | UTC

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 – JAMA Network Open

Commentaries:

Single-Dose Ad26.COV2.S Vaccine—Room for Improvement – JAMA Network Open

Real-world study shows J&J COVID-19 vaccine 74% effective – CIDRAP

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

[Preprint] Observational study finds single-dose Johnson & Johnson vaccine is 76.7% effective in preventing SARS-CoV-2 infection

RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351

WHO issues emergency use approval for India’s Covaxin.

4 Nov, 2021 | 10:11h | UTC

WHO issues emergency use listing for eighth COVID-19 vaccine – World Health Organization

Commentaries:

WHO Gives India’s Covaxin Approval, Opening the Door to COVAX distribution – Health Policy Watch

WHO green-lights India’s COVID vaccine as global cases rise – CIDRAP

Commentary on Twitter (thread – click for more)

? WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. pic.twitter.com/dp2A1knGtT

— World Health Organization (WHO) (@WHO) November 3, 2021

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

4 Nov, 2021 | 10:06h | UTC

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Commentaries:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

4 Nov, 2021 | 10:00h | UTC

Ten Things to Know About MIS-C – American College of Cardiology

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

The USPSTF draft statement recommends against screening for chronic obstructive pulmonary disease in asymptomatic adults.

4 Nov, 2021 | 09:56h | UTC

Chronic Obstructive Pulmonary Disease: Screening – U.S. Preventive Services Task Force

Commentary: USPSTF Still Advises Against COPD Screening for Asymptomatic Adults – HealthDay

ASH Guideline issued a conditional recommendation against routine use of outpatient anticoagulant prophylaxis in patients with COVID-19 being discharged from the hospital.

4 Nov, 2021 | 10:03h | UTC

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis – Blood Advances

M-A: Zinc might help to stave off respiratory infection symptoms and cut illness duration – “But quality of evidence variable, and no clarity on optimal formulation or dose”.

4 Nov, 2021 | 09:53h | UTC

News Release: Zinc might help to stave off respiratory infection symptoms and cut illness duration – BMJ

Original Study: Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials – BMJ Open

Commentary on Twitter

A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence, published in @BMJ_Open https://t.co/Nq5KadAw5y

— BMJ (@bmj_company) November 2, 2021

Review: Lower carbohydrate diets for adults with type 2 diabetes.

4 Nov, 2021 | 09:55h | UTC

Lower carbohydrate diets for adults with type 2 diabetes – British Journal of Nutrition

Meta-analysis of randomized trials: patients adhering to a low carbohydrate diet for six months may experience remission of diabetes without adverse consequences

Low carbohydrate diet: Insights from a general practice service in patients with type 2 diabetes

Position Statement on Low-Carbohydrate Diets for Adults with Diabetes

Low Carbohydrate Diets for Diabetes: A Review of the Clinical Effectiveness and Guidelines

Systematic Review: Low‐carbohydrate Diets for Type 2 Diabetes Management

Practical Guide: Adapting Diabetes Medication for Low Carbohydrate Management of Type 2 Diabetes

Observational Study: Management of Type 1 Diabetes With a Very Low–Carbohydrate Diet

Study: Dietary Carbohydrate Restriction Improves Metabolic Syndrome Independent of Weight Loss

Research: Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

4 Nov, 2021 | 09:58h | UTC

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

Commentary on Twitter

NEW—Cervical cancer rates 87% lower in women offered vaccination against human papillomavirus (#HPV) between ages 12-13 than in previous generations, English study confirms.

First direct evidence of cervical cancer prevention using bivalent vaccine: https://t.co/HdQbGIKxZp pic.twitter.com/PMFermHGOv

— The Lancet (@TheLancet) November 3, 2021